
    
      This is a randomized, double-blind, double-dummy, multi-center, parallel-group study.
      Subjects who meet the eligibility criteria at Screening and at the end of a 2-week Run-In
      Period will enter a 12-week Treatment Period. There will be a 7-day Follow-up Period after
      the Treatment Period.
    
  